Agilis Biothera Completes $8M Financing to Treat Rare Diseases
January 03, 2014
Agilis Biotherapeutics, a synthetic biology-based company focused on rare genetic diseases, has completed an $8 million financing. Proceeds will be used for the company's initial focus, developing a treatment for Friedrich's ataxia (FRDA) in collaboration with Intrexon. Agilis and Intrexon recently executed an Exclusive Channel Collaboration (ECC) through which Agilis intends to develop and commercialize DNA-based therapeutics for the treatment of FRDA. Under the ECC, Agilis also can opt to expand its relationship with Intrexon by adding another rare genetic disease to the collaboration.